转移性肾细胞癌-话题@MedSci

#转移性肾细胞癌#

54篇内容 | 1987人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2200847, encodeId=2c89220084e8a, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=转移性肾细胞癌预后评估(Meet-URO得分), objectType=article, longId=823726, objectId=8adb823e26e1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221120/1669014360481_4754896.webp, objectUrl=/article/show_article.do?id=8adb823e26e1, replyNumber=0, likeNumber=30, createdTime=2024-04-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8adb823e26e1, moduleTitle=转移性肾细胞癌预后评估(Meet-URO得分), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8adb823e26e1)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1420334, encodeId=2b1014203349b, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=JAMA Netw open：转移性肾细胞癌患者“免疫-肿瘤联合治疗”后的影像学反应, objectType=article, longId=730177, objectId=5ba9e3017707, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ba9e3017707, replyNumber=0, likeNumber=74, createdTime=2022-06-23, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ba9e3017707, moduleTitle=JAMA Netw open：转移性肾细胞癌患者“免疫-肿瘤联合治疗”后的影像学反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ba9e3017707)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420333, encodeId=c4761420333d9, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Eur Urol：立体定向放疗和短期派姆单抗治疗寡转移性肾细胞癌的疗效和安全性评估 , objectType=article, longId=293393, objectId=a91729339309, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a91729339309, replyNumber=0, likeNumber=68, createdTime=2022-01-05, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a91729339309, moduleTitle=Eur Urol：立体定向放疗和短期派姆单抗治疗寡转移性肾细胞癌的疗效和安全性评估 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a91729339309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420332, encodeId=b46f142033232, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Front Oncol：甲状腺激素比值对晚期转移性肾细胞癌患者的预后价值:来自Meet-URO 14研究, objectType=article, longId=221109, objectId=e61322110956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e61322110956, replyNumber=0, likeNumber=137, createdTime=2021-11-28, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e61322110956, moduleTitle=Front Oncol：甲状腺激素比值对晚期转移性肾细胞癌患者的预后价值:来自Meet-URO 14研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e61322110956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420331, encodeId=76031420331b9, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Clin Cancer Res：大剂量IL-2联合立体定向消融放疗治疗转移性肾细胞癌的疗效, objectType=article, longId=220861, objectId=4919220861ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4919220861ca, replyNumber=0, likeNumber=62, createdTime=2021-11-24, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4919220861ca, moduleTitle=Clin Cancer Res：大剂量IL-2联合立体定向消融放疗治疗转移性肾细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4919220861ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420330, encodeId=b84614203308a, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, objectType=article, longId=219184, objectId=9df12191846b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9df12191846b, replyNumber=0, likeNumber=60, createdTime=2021-10-26, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9df12191846b, moduleTitle=The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9df12191846b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420329, encodeId=38ca142032917, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效, objectType=article, longId=219179, objectId=3d182191e9b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d182191e9b7, replyNumber=0, likeNumber=132, createdTime=2021-10-26, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d182191e9b7, moduleTitle=The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d182191e9b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420328, encodeId=63f0142032870, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Eur J Cancer: 卡博替尼（Cabozantinib）治疗转移性肾细胞癌的疗效：来自真实世界研究CABOREAL结果分析, objectType=article, longId=219150, objectId=a7ac21915026, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ac21915026, replyNumber=0, likeNumber=76, createdTime=2021-10-25, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ac21915026, moduleTitle=Eur J Cancer: 卡博替尼（Cabozantinib）治疗转移性肾细胞癌的疗效：来自真实世界研究CABOREAL结果分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ac21915026)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420327, encodeId=209e142032e1b, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=J Immunother Cancer：Ipilimumab+Nivolumab治疗转移性肾细胞癌伴有脑转移患者的疗效, objectType=article, longId=217179, objectId=edee21e17926, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=edee21e17926, replyNumber=0, likeNumber=68, createdTime=2021-09-17, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=edee21e17926, moduleTitle=J Immunother Cancer：Ipilimumab+Nivolumab治疗转移性肾细胞癌伴有脑转移患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=edee21e17926)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420326, encodeId=1b63142032611, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Eur Urol：转移性肾细胞癌患者寡进展的立体定向放射治疗 , objectType=article, longId=216308, objectId=f8e521630891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8e521630891, replyNumber=0, likeNumber=65, createdTime=2021-08-27, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8e521630891, moduleTitle=Eur Urol：转移性肾细胞癌患者寡进展的立体定向放射治疗 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8e521630891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420325, encodeId=6d541420325ee, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Front Oncol：免疫检查点阻断治疗转移性肾细胞癌患者在临床结果方面的种族差异, objectType=article, longId=214306, objectId=a51f214306eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a51f214306eb, replyNumber=0, likeNumber=55, createdTime=2021-07-17, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a51f214306eb, moduleTitle=Front Oncol：免疫检查点阻断治疗转移性肾细胞癌患者在临床结果方面的种族差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a51f214306eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420324, encodeId=a4c714203245a, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Eur Urol：单独使用舒尼替尼或在肾切除术后使用舒尼替尼治疗转移性肾细胞癌患者 , objectType=article, longId=214148, objectId=0c7921414807, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7921414807, replyNumber=0, likeNumber=67, createdTime=2021-07-14, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7921414807, moduleTitle=Eur Urol：单独使用舒尼替尼或在肾切除术后使用舒尼替尼治疗转移性肾细胞癌患者 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0c7921414807)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420323, encodeId=5778142032369, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Eur Urol：Nivolumab治疗转移性肾细胞癌的患者的原发性肾肿瘤反应 , objectType=article, longId=213725, objectId=ecda213e25ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecda213e25ad, replyNumber=0, likeNumber=0, createdTime=2021-07-06, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecda213e25ad, moduleTitle=Eur Urol：Nivolumab治疗转移性肾细胞癌的患者的原发性肾肿瘤反应 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecda213e25ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420322, encodeId=84ba1420322cd, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Lancet oncol：乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期！, objectType=article, longId=212814, objectId=199e212814dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=199e212814dc, replyNumber=0, likeNumber=87, createdTime=2021-06-18, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=199e212814dc, moduleTitle=Lancet oncol：乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=199e212814dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420321, encodeId=3ea31420321d3, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Eur Urol：转移性肾细胞癌患者接受Atezolizumab或Sunitinib单药治疗疾病进展后使用Atezolizumab加Bevacizumab的疗效和安全性 , objectType=article, longId=208763, objectId=25ad208e63d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ad208e63d1, replyNumber=0, likeNumber=68, createdTime=2021-03-22, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ad208e63d1, moduleTitle=Eur Urol：转移性肾细胞癌患者接受Atezolizumab或Sunitinib单药治疗疾病进展后使用Atezolizumab加Bevacizumab的疗效和安全性 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25ad208e63d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420320, encodeId=4c1b14203207c, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Sci Rep：循环肿瘤DNA作为转移性肾细胞癌中免疫检查点阻断治疗反应的预测因子表现研究, objectType=article, longId=208521, objectId=ca8a20852107, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca8a20852107, replyNumber=0, likeNumber=55, createdTime=2021-03-18, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca8a20852107, moduleTitle=Sci Rep：循环肿瘤DNA作为转移性肾细胞癌中免疫检查点阻断治疗反应的预测因子表现研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca8a20852107)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420319, encodeId=836a142031984, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=ASCO GU 2021: 纳武利尤单抗+伊匹单抗联合治疗转移性肾细胞癌的疗效, objectType=article, longId=207272, objectId=f72f20e272b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f72f20e272b6, replyNumber=0, likeNumber=158, createdTime=2021-02-20, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f72f20e272b6, moduleTitle=ASCO GU 2021: 纳武利尤单抗+伊匹单抗联合治疗转移性肾细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f72f20e272b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420318, encodeId=5557142031881, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？, objectType=article, longId=207195, objectId=8fad20e19548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fad20e19548, replyNumber=0, likeNumber=0, createdTime=2021-02-18, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fad20e19548, moduleTitle=ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fad20e19548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420317, encodeId=0eab142031eb3, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Eur Urol Oncol：选择转移性肾细胞癌患者中进行减瘤性肾切除术的更佳候选者的一种新的风险评分开发, objectType=article, longId=205986, objectId=3fd020598612, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fd020598612, replyNumber=0, likeNumber=111, createdTime=2021-01-23, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fd020598612, moduleTitle=Eur Urol Oncol：选择转移性肾细胞癌患者中进行减瘤性肾切除术的更佳候选者的一种新的风险评分开发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fd020598612)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1420316, encodeId=9c1314203164a, content=<a href='/topic/show?id=5ed393430f3' target=_blank style='color:#2F92EE;'>#转移性肾细胞癌#</a>, objectTitle=Radiology：转移性肾细胞癌化疗后有没有效如何看？, objectType=article, longId=204280, objectId=cf0020428046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0020428046, replyNumber=0, likeNumber=66, createdTime=2020-12-09, rootId=0, userName=zhangyxzsh, userId=0da33575570, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0020428046, moduleTitle=Radiology：转移性肾细胞癌化疗后有没有效如何看？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0020428046)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

转移性肾细胞癌

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

转移性肾细胞癌预后评估(Meet-URO得分)

2024-04-28发表于上海

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

JAMA Netw open：转移性肾细胞癌患者“免疫-肿瘤联合治疗”后的影像学反应

2022-06-23

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Eur Urol：立体定向放疗和短期派姆单抗治疗寡转移性肾细胞癌的疗效和安全性评估

2022-01-05

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Front Oncol：甲状腺激素比值对晚期转移性肾细胞癌患者的预后价值:来自Meet-URO 14研究

2021-11-28

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Clin Cancer Res：大剂量IL-2联合立体定向消融放疗治疗转移性肾细胞癌的疗效

2021-11-24

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

The Oncologist：PPIs的联合使用对Cabozantinib（卡博替尼）治疗转移性肾细胞癌(mRCC)的影响

2021-10-26

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

The Oncologist：仑伐替尼联合或不联合依维莫司（Len ±Eve）治疗转移性肾细胞癌(mRCC)的疗效

2021-10-26

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Eur J Cancer: 卡博替尼（Cabozantinib）治疗转移性肾细胞癌的疗效：来自真实世界研究CABOREAL结果分析

2021-10-25

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

J Immunother Cancer：Ipilimumab+Nivolumab治疗转移性肾细胞癌伴有脑转移患者的疗效

2021-09-17

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Eur Urol：转移性肾细胞癌患者寡进展的立体定向放射治疗

2021-08-27

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Front Oncol：免疫检查点阻断治疗转移性肾细胞癌患者在临床结果方面的种族差异

2021-07-17

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Eur Urol：单独使用舒尼替尼或在肾切除术后使用舒尼替尼治疗转移性肾细胞癌患者

2021-07-14

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Eur Urol：Nivolumab治疗转移性肾细胞癌的患者的原发性肾肿瘤反应

2021-07-06

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Lancet oncol：乐伐替尼联合派姆单抗治疗转移性肾细胞癌的疗效可期！

2021-06-18

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Eur Urol：转移性肾细胞癌患者接受Atezolizumab或Sunitinib单药治疗疾病进展后使用Atezolizumab加Bevacizumab的疗效和安全性

2021-03-22

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Sci Rep：循环肿瘤DNA作为转移性肾细胞癌中免疫检查点阻断治疗反应的预测因子表现研究

2021-03-18

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

ASCO GU 2021: 纳武利尤单抗+伊匹单抗联合治疗转移性肾细胞癌的疗效

2021-02-20

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

ASCO GU 2021: 转移性肾细胞癌一线采用免疫治疗效果如何？

2021-02-18

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Eur Urol Oncol：选择转移性肾细胞癌患者中进行减瘤性肾切除术的更佳候选者的一种新的风险评分开发

2021-01-23

zhangyxzsh (审核中...)

前往app查看评论内容

#转移性肾细胞癌#

Radiology：转移性肾细胞癌化疗后有没有效如何看？

2020-12-09

科室
- - 订阅+
  - 更多科室
工具
服务